BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35272025)

  • 1. A Risk Model to Predict the Delivery of Adjuvant Chemotherapy Following Lung Resection in Patients With Pathologically Positive Lymph Nodes.
    Patella M; Brunelli A; Adams L; Cafarotti S; Costardi L; De Leyn P; Decaluwé H; Franks KN; Fuentes M; Jimenez MF; Karri S; Moons J; Novellis P; Ruffini E; Veronesi G; Voulaz E; Shargall Y
    Semin Thorac Cardiovasc Surg; 2023; 35(2):387-398. PubMed ID: 35272025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Isaka M; Kojima H; Takahashi S; Omae K; Ohde Y
    Lung Cancer; 2018 Jan; 115():28-33. PubMed ID: 29290258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical Results in Pathological N1 Nonsmall Cell Lung Cancer.
    Yoshida Y; Yotsukura M; Nakagawa K; Watanabe H; Motoi N; Watanabe SI
    Thorac Cardiovasc Surg; 2021 Jun; 69(4):366-372. PubMed ID: 32634835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy and Surgical Resection for N1 Positive Non-small Cell Lung Cancer: Better Than Expected Outcomes.
    White A; Kucukak S; Lee DN; Mazzola E; Dolan D; Bueno R; Jaklitsch MT; Swanson SJ
    Semin Thorac Cardiovasc Surg; 2021; 33(4):1105-1111. PubMed ID: 33600992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease.
    Razi SS; Nguyen D; Villamizar N
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2469-2483.e4. PubMed ID: 31928821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer.
    Osarogiagbon RU; Allen JW; Farooq A; Berry A; O'Brien T
    Ann Thorac Surg; 2011 May; 91(5):1486-92. PubMed ID: 21524460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.
    Smeltzer MP; Faris NR; Ray MA; Osarogiagbon RU
    JAMA Oncol; 2018 Jan; 4(1):80-87. PubMed ID: 28973110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors for hilar/intrapulmonary lymph node metastasis in discrete type of clinical N1 non-small cell lung cancer.
    Fukui T; Kato K; Okasaka T; Kawaguchi K; Fukumoto K; Nakamura S; Hakiri S; Ozeki N; Yokoi K
    Gen Thorac Cardiovasc Surg; 2017 Nov; 65(11):640-645. PubMed ID: 28866794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
    Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
    Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis.
    Yang CF; Kumar A; Gulack BC; Mulvihill MS; Hartwig MG; Wang X; D'Amico TA; Berry MF
    J Thorac Cardiovasc Surg; 2016 May; 151(5):1380-8. PubMed ID: 26874598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis of 220 patients with completely resected stage-II non-small cell lung cancer.
    Dai Y; Su XD; Long H; Lin P; Fu JH; Zhang LJ; Wang X; Wen ZS; Zhu ZH; Zhang X; Rong TH
    Chin J Cancer; 2010 May; 29(5):538-44. PubMed ID: 20426905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors for Surgically Resected N2 Non-small Cell Lung Cancer.
    Kawasaki K; Sato Y; Suzuki Y; Saito H; Nomura Y; Yoshida Y
    Ann Thorac Cardiovasc Surg; 2015; 21(3):217-22. PubMed ID: 25641029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.
    Taylor MD; LaPar DJ; Thomas CJ; Persinger M; Stelow EB; Kozower BD; Lau CL; Jones DR
    Ann Thorac Surg; 2013 Oct; 96(4):1163-1170. PubMed ID: 23998409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological outcomes after lobe-specific mediastinal lymph node dissection via multiport video-assisted thoracoscopic surgery.
    Mun M; Nakao M; Matsuura Y; Ichinose J; Okumura S
    Eur J Cardiothorac Surg; 2020 Aug; 58(Suppl_1):i92-i99. PubMed ID: 32533183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
    Yan D; Wei P; An G; Chen W
    J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.
    Ohtaki Y; Shimizu K; Kaira K; Nagashima T; Obayashi K; Nakazawa S; Kakegawa S; Igai H; Kamiyoshihara M; Nishiyama M; Takeyoshi I
    Surg Today; 2016 Oct; 46(10):1196-208. PubMed ID: 26782692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
    Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.